Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis
Authors:
Open Access
- 3 July 2022
- journal article
- research article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 307 (3) , 927-935
Abstract
Purpose: Uterine sarcoma (US) as a histologically heterogeneous group of tumors is rare and associated with poor prognosis. Prognostic factors based on systematic data collection need to be identified to optimize patients’ treatment. Methods: This unicenter, retrospective cohort study includes 57 patients treated at the University Hospital Freiburg, Germany between 1999 and 2017. Progression-free survival (PFS) and overall survival (OS) were calculated and visualized in Kaplan–Meier curves. Prognostic factors were identified using log-rank test and Cox regression. Results: 44 Leiomyosarcoma (LMS), 7 low-grade endometrial stromal sarcoma (LG-ESS), 4 high-grade ESS and 2 undifferentiated US patients were identified. The median age at time of diagnosis was 51.0 years (range 18–83). The median follow-up time was 35 months. PFS for the total cohort was 14.0 (95%-Confidence-Interval (CI) 9.7–18.3) and OS 36.0 months (95%-CI 22.1–49.9). Tumor pathology was prognostically significant for OS with LG-ESS being the most favorable (mean OS 150.3 months). In the multivariate analysis, patients over 52 years showed a four times higher risk for tumor recurrence (hazard ratio (HR) 4.4; 95%-CI 1.5–12.9). Progesterone receptor negativity was associated with a two times higher risk for death (HR 2.8; 95%-CI 1.0–7.5). For LMS patients age ≥ 52 years (p = 0.04), clear surgical margins (p = 0.01), FIGO stage (p = 0.01) and no application of chemotherapy (p = 0.02) were statistically significant factors for OS. Conclusion: Tumor histology, age at time of diagnosis and progesterone receptor status were prognostic factors for US. Unfavorable OS in LMS patients was associated with advanced FIGO stage, suboptimal cytoreduction and application of chemotherapy.Keywords
All Related Versions
Funding Information
- Albert-Ludwigs-Universität Freiburg im Breisgau
This publication has 29 references indexed in Scilit:
- Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcomaCancer, 2014
- Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?Gynecologic Oncology, 2013
- Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE projectEuropean Journal of Cancer, 2013
- Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcomaCancer, 2013
- A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma GroupAnnals of Oncology, 2012
- Uterine sarcomas: A reviewGynecologic Oncology, 2010
- Prognostic Factors in Early-Stage Leiomyosarcoma of the UterusInternational Journal of Gynecological Cancer, 2009
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- Prognostic factors and survival in 1396 patients with uterine leiomyosarcomasCancer, 2008
- Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcomaCancer, 2004